A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy
A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy
复制标题
DOI：
10.1097/coc.0000000000000311
复制
发表时间：
2018-05-01
影响因子：
2.6
通讯作者：
Kamrava, Mitchell
中科院分区：
文献类型：
--
作者：
Hegde, John V.;Collins, Sean P.;Kamrava, Mitchell
目的：研究接受立体定向体部放疗（SBRT）或高剂量率近距离放射治疗（HDR-B）单药治疗的国家综合癌症网络定义的中危前列腺癌（PC）患者的生化无复发生存率（BRFS）。材料和方法：对437例接受SBRT（N = 300）或HDR-B（N = 137）治疗的中危PC患者进行了回顾性多机构分析。接受SBRT的男性接受35至40戈伊分4至5次治疗。共95.6%接受HDR-B的患者接受了6次42戈伊的治疗。使用T检验比较连续变量的基线患者特征，使用Mantel-Haenszel卡方检验或Fisher精确检验比较分类变量的基线患者特征。生成Kaplan-Meier曲线以估计5年精算BRFS。采用考克斯比例风险模型进行多变量分析，以评估与生化failure.Results相关的因素：诊断时的平均年龄为68.4（SD +/- 7.8）岁。T分类为T1占63.6%，T2占36.4%。平均初始前列腺特异性抗原为7.4（SD +/- 3.4）ng/mL。活检Gleason评分为
Objectives: To investigate biochemical relapse-free survival (BRFS) in men with National Comprehensive Cancer Network-defined intermediate-risk prostate cancer (PC) treated with either stereotactic body radiotherapy (SBRT) or high-dose-rate brachytherapy (HDR-B) monotherapy.Materials and Methods: A retrospective, multi-institutional analysis of 437 patients with intermediate-risk PC treated with SBRT (N = 300) or HDR-B (N = 137) was performed. Men who underwent SBRT were treated to 35 to 40 Gy in 4 to 5 fractions. A total of 95.6% who underwent HDR-B were treated to 42 Gy in 6 fractions. Baseline patient characteristics were compared using a T test for continuous variables and the Mantel-Haenszel chi(2) metric or Fisher exact test for categorical variables. Kaplan-Meier curves were generated to estimate 5-year actuarial BRFS. Multivariate analysis using a Cox proportional-hazards model was used to evaluate factors associated with biochemical failure.Results: The mean age at diagnosis was 68.4 (SD +/- 7.8) years. T-category was T1 in 63.6% and T2 in 36.4%. Mean initial prostate-specific antigen was 7.4 (SD +/- 3.4) ng/mL. Biopsy Gleason score was